Colchicine for acute gout

医学 秋水仙碱 痛风 随机对照试验 荟萃分析 内科学 物理疗法 安慰剂 不利影响 重症监护医学 替代医学 病理
作者
Bayden J McKenzie,Mihir D. Wechalekar,Renea V Johnston,Naomi Schlesinger,Rachelle Buchbinder
出处
期刊:The Cochrane library [Elsevier BV]
卷期号:2021 (8) 被引量:28
标识
DOI:10.1002/14651858.cd006190.pub3
摘要

This is an updated Cochrane Review, first published in 2006 and updated in 2014. Gout is one of the most common rheumatic diseases worldwide. Despite the use of colchicine as one of the first-line therapies for the treatment of acute gout, evidence for its benefits and harms is relatively limited.To update the available evidence of the benefits and harms of colchicine for the treatment of acute gout.We updated the search of CENTRAL, MEDLINE, Embase, Clinicaltrials.gov and WHO ICTRP registries to 28 August 2020. We did not impose any date or language restrictions in the search.We considered published randomised controlled trials (RCTs) and quasi-randomised controlled trials (quasi-RCTs) evaluating colchicine therapy compared with another therapy (placebo or active) in acute gout; low-dose colchicine at clinically relevant doses compared with placebo was the primary comparison. The major outcomes were pain, participant global assessment of treatment success (proportion with 50% or greater decrease in pain from baseline up to 32 to 36 hours), reduction of inflammation, function of target joint, serious adverse events, total adverse events and withdrawals due to adverse events.We used standard methodological procedures as expected by Cochrane in this review update.We included four trials (803 randomised participants), including two new trials, in this updated review. One three-arm trial compared high-dose colchicine (52 participants), low-dose colchicine (74 participants) and placebo (59 participants); one trial compared high-dose colchicine with placebo (43 participants); one trial compared low-dose colchicine with non-steroidal anti-inflammatory drugs (NSAIDs) (399 participants); and one trial compared low-dose colchicine with Chuanhu anti-gout mixture (traditional Chinese Medicine compound) (176 participants). We did not identify any trials comparing colchicine to glucocorticoids (by any route). The mean age of participants ranged from 51.2 to 70 years, and trial duration from 48 hours to 12 weeks. Two trials were at low risk of bias, one was possibly susceptible to selection bias (random sequence generation), reporting bias and other bias, and one open-label trial was at high risk of performance and detection bias. For the primary comparison, low-quality evidence from one trial (103 participants, downgraded for imprecision and bias) suggests low-dose colchicine may improve treatment outcome compared to placebo with little or no increased risk of adverse events. The number of people who reported treatment success (50% or greater pain reduction) at 32 to 36 hours was slightly larger with low-dose colchicine (418 per 1000) compared with placebo (172 per 1000; risk ratio (RR) 2.43, 95% confidence interval (CI) 1.05 to 5.64; absolute improvement 25% more reported success (7% more to 42% more, the 95% CIs include both a clinically important and unimportant benefit); relative change of 143% more people reported treatment success (5% more to 464% more). The incidence of total adverse events was 364 per 1000 with low-dose colchicine compared with 276 per 1000 with placebo: RR 1.32, 95% CI 0.68 to 2.56; absolute difference 9% more events with low-dose colchicine (9% fewer to 43% more, the 95% CIs include both a clinically important effect and no effect); relative change of 32% more events (32% fewer to 156% more). No participants withdrew due to adverse events or reported any serious adverse events. Pain, inflammation and function were not reported. Low-quality evidence (downgraded for imprecision and bias) from two trials (124 participants) suggests that high-dose colchicine compared to placebo may improve symptoms, but with increased risk of harms. More participants reported treatment success at 32 to 36 hours with high-dose colchicine (518 per 1000) compared with placebo (240 per 1000): RR 2.16, 95% CI 1.28 to 3.65, absolute improvement 28% (8% more to 46% more); more also had reduced inflammation at this time point with high-dose colchicine (504 per 1000) compared with placebo (48 per 1000): RR 10.50, 95% CI 1.48 to 74.38; absolute improvement 45% greater (22% greater to 68% greater); but more adverse events were reported with high-dose colchicine (829 per 1000 compared with 260 per 1000): RR 3.21, 95% CI 2.01 to 5.11, absolute difference 57% (26% more to 74% more). Pain and function were not reported. Low-quality evidence from a single trial comparing high-dose to low-dose colchicine indicates there may be little or no difference in benefit in terms of treatment success at 32 to 36 hours but more adverse events associated with the higher dose. Similarly, low-quality evidence from a single trial indicates there may also be little or no benefit of low-dose colchicine over NSAIDs in terms of treatment success and pain reduction at seven days, with a similar number of adverse events reported at four weeks follow-up. Reduction of inflammation, function of target joint and withdrawals due to adverse events were not reported in either of these trials, and pain was not reported in the high-dose versus low-dose colchicine trial. We were unable to estimate the risk of serious adverse events for most comparisons as there were few events reported in the trials. One trial (399 participants) reported three serious adverse (one in a participant receiving low-dose colchicine and two in participants receiving NSAIDs), due to reasons unrelated to the trial (low-quality evidence downgraded for bias and imprecision).We found low-quality evidence that low-dose colchicine may be an effective treatment for acute gout when compared to placebo and low-quality evidence that its benefits may be similar to NSAIDs. We downgraded the evidence for bias and imprecision. While both high- and low-dose colchicine improve pain when compared to placebo, low-quality evidence suggests that high-dose (but not low-dose) colchicine may increase the number of adverse events compared to placebo, while low-quality evidence indicates that the number of adverse events may be similar with low-dose colchicine and NSAIDs. Further trials comparing colchicine to placebo or other treatment will likely have an important impact on our confidence in the effect estimates and may change the conclusions of this review. There are no trials reporting the effect of colchicine in populations with comorbidities or in comparison with other commonly used treatments, such as glucocorticoids.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1秒前
molihuakai的应助被Code_king采纳,获得10
2秒前
小二郎的应助被Code_king采纳,获得10
3秒前
丘比特的应助被Code_king采纳,获得10
3秒前
molihuakai的应助被Code_king采纳,获得10
3秒前
小二郎的应助被Code_king采纳,获得10
3秒前
Lucas的应助被Code_king采纳,获得10
3秒前
Roselle发布了新的文献求助10
3秒前
3秒前
情怀的应助被Code_king采纳,获得10
3秒前
Hello的应助被Code_king采纳,获得10
3秒前
ding的应助被Code_king采纳,获得10
3秒前
科目三的应助被Code_king采纳,获得10
3秒前
3秒前
whs发布了新的文献求助10
3秒前
优美的冷雪的应助被嘻嘻哈哈采纳,获得210
4秒前
个性的一手完成签到,获得积分10
4秒前
5秒前
杜杨帆发布了新的文献求助10
6秒前
gsy发布了新的文献求助10
6秒前
偤萸完成签到,获得积分10
7秒前
筑梦之鱼发布了新的文献求助10
8秒前
WangW完成签到,获得积分10
8秒前
上海自来水来自海水完成签到,获得积分10
9秒前
9秒前
daomaihu发布了新的文献求助100
10秒前
guo7700完成签到,获得积分10
10秒前
10秒前
不爱喝酒的应助被威武的绿兰采纳,获得10
11秒前
orixero的应助被企鹅采纳,获得10
11秒前
习二的应助被尹相汛采纳,获得20
11秒前
12秒前
打打的应助被Code_king采纳,获得10
13秒前
隐形曼青的应助被Code_king采纳,获得10
13秒前
852的应助被Code_king采纳,获得10
13秒前
英俊的铭的应助被Code_king采纳,获得10
13秒前
13秒前
orixero的应助被Code_king采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177614
求助须知:如何正确求助?哪些是违规求助? 9568432
关于积分的说明 21799252
捐赠科研通 7772168
什么是DOI,文献DOI怎么找? 3432399
关于科研通互助平台的介绍 2556593
邀请新用户注册赠送积分活动 2477966